Company intelligence / Profile preview

Carlsson Research

Ownership: Private
Development stage: Other

Overview

Carlsson Research was a Swedish biopharmaceutical company specializing in the discovery and development of small molecule drugs targeting central nervous system disorders. Its most advanced asset was Huntexil® (pridopidine), developed for Huntington's disease. The company also developed ordopidine and seridopidine. In August 2006, it was acquired by NeuroSearch A/S, which continued clinical development of its pipeline.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Carlsson Research.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carlsson Research.

Explore the full profile